Kiniksa Pharmaceuticals International (KNSA) Other Operating Expenses (2017 - 2026)
Kiniksa Pharmaceuticals International filings provide 6 years of Other Operating Expenses readings, the most recent being $96.4 million for Q1 2026.
- On a quarterly basis, Other Operating Expenses rose 50.62% to $96.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $341.9 million, a 54.15% increase, with the full-year FY2025 number at $307.2 million, up 62.36% from a year prior.
- Other Operating Expenses hit $96.4 million in Q1 2026 for Kiniksa Pharmaceuticals International, up from $91.0 million in the prior quarter.
- In the past five years, Other Operating Expenses ranged from a high of $96.4 million in Q1 2026 to a low of $8.7 million in Q2 2022.
- Median Other Operating Expenses over the past 5 years was $31.4 million (2024), compared with a mean of $43.1 million.
- Biggest five-year swings in Other Operating Expenses: soared 317.78% in 2022 and later grew 22.86% in 2023.
- Kiniksa Pharmaceuticals International's Other Operating Expenses stood at $14.2 million in 2022, then skyrocketed by 86.36% to $26.5 million in 2023, then skyrocketed by 149.16% to $66.1 million in 2024, then surged by 37.66% to $91.0 million in 2025, then increased by 5.93% to $96.4 million in 2026.
- The last three reported values for Other Operating Expenses were $96.4 million (Q1 2026), $91.0 million (Q4 2025), and $83.6 million (Q3 2025) per Business Quant data.